Published in Int J Cancer on February 10, 2005
Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer (2006) 2.45
Stat3 promotes metastatic progression of prostate cancer. Am J Pathol (2008) 1.85
Pathobiological implications of the expression of EGFR, pAkt, NF-κB and MIC-1 in prostate cancer stem cells and their progenies. PLoS One (2012) 1.06
LNCaP Atlas: gene expression associated with in vivo progression to castration-recurrent prostate cancer. BMC Med Genomics (2010) 1.04
Hierarchical clustering of immunohistochemical analysis of the activated ErbB/PI3K/Akt/NF-kappaB signalling pathway and prognostic significance in prostate cancer. Br J Cancer (2010) 1.02
Integrin signaling aberrations in prostate cancer. Am J Transl Res (2009) 1.01
Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells. Mol Cancer Ther (2010) 1.01
Proteoglycans in prostate cancer. Nat Rev Urol (2012) 0.99
Identification of genes regulating migration and invasion using a new model of metastatic prostate cancer. BMC Cancer (2014) 0.98
MUC-1 gene is associated with prostate cancer death: a 20-year follow-up of a population-based study in Sweden. Br J Cancer (2007) 0.96
Functions of normal and malignant prostatic stem/progenitor cells in tissue regeneration and cancer progression and novel targeting therapies. Endocr Rev (2008) 0.92
Matriptase is involved in ErbB-2-induced prostate cancer cell invasion. Am J Pathol (2010) 0.91
Decreased adhesiveness, resistance to anoikis and suppression of GRP94 are integral to the survival of circulating tumor cells in prostate cancer. Clin Exp Metastasis (2008) 0.91
Identification of EpCAM as a molecular target of prostate cancer stroma. Am J Pathol (2009) 0.91
Imaging primary prostate cancer with 11C-Choline PET/CT: relation to tumour stage, Gleason score and biomarkers of biologic aggressiveness. Radiol Oncol (2012) 0.90
Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases. J Pathol (2013) 0.88
Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer. Prostate Cancer Prostatic Dis (2013) 0.87
Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway. Adv Urol (2012) 0.86
Epidermal growth factor promotes protein degradation of epithelial protein lost in neoplasm (EPLIN), a putative metastasis suppressor, during epithelial-mesenchymal transition. J Biol Chem (2012) 0.85
Molecular staging of prostate cancer in the year 2007. World J Urol (2007) 0.85
PSMA, EpCAM, VEGF and GRPR as imaging targets in locally recurrent prostate cancer after radiotherapy. Int J Mol Sci (2014) 0.84
STAT5A/B gene locus undergoes amplification during human prostate cancer progression. Am J Pathol (2013) 0.84
Expression of parvin-beta is a prognostic factor for patients with urothelial cell carcinoma of the upper urinary tract. Br J Cancer (2010) 0.81
Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer. Front Oncol (2016) 0.79
At the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of bone. Odontology (2012) 0.78
MUC1 is upregulated in advanced prostate cancer and is an independent prognostic factor. Prostate Cancer Prostatic Dis (2016) 0.77
RAMP1 is a direct NKX3.1 target gene up-regulated in prostate cancer that promotes tumorigenesis. Am J Pathol (2013) 0.77
Nuclear Ep-ICD expression is a predictor of poor prognosis in "low risk" prostate adenocarcinomas. PLoS One (2015) 0.76
Profiling serum HER-2/NEU in prostate cancer. Hippokratia (2013) 0.75
Qualitative and Quantitative Requirements for Assessing Prognostic Markers in Prostate Cancer. Microarrays (Basel) (2014) 0.75
Gαs protein expression is an independent predictor of recurrence in prostate cancer. J Immunol Res (2014) 0.75
Apoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic Hyperplasia. Int J Mol Sci (2016) 0.75
EpCAM Expression in Lymph Node and Bone Metastases of Prostate Carcinoma: A Pilot Study. Int J Mol Sci (2016) 0.75
Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med (2002) 5.34
Frequent EpCam protein expression in human carcinomas. Hum Pathol (2004) 4.94
Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant (2003) 4.54
Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation (2005) 3.57
HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol (2009) 3.37
Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res (2005) 2.85
FAN1 mutations cause karyomegalic interstitial nephritis, linking chronic kidney failure to defective DNA damage repair. Nat Genet (2012) 2.74
Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res (2004) 2.55
Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat Genet (2004) 2.44
Prevalence of KIT expression in human tumors. J Clin Oncol (2004) 2.40
GreenLight laser vaporization of the prostate: single-center experience and long-term results after 500 procedures. Eur Urol (2008) 2.33
Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes. Am J Kidney Dis (2008) 2.24
Patterns of pulmonary complications associated with sirolimus. Respiration (2005) 2.20
Variability in diagnostic opinion among pathologists for single small atypical foci in prostate biopsies. Am J Surg Pathol (2010) 2.16
The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology (2011) 2.15
High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat (2004) 2.14
MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine (Baltimore) (2003) 2.05
Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol (2004) 2.04
Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am J Hum Genet (2002) 1.86
Stat3 promotes metastatic progression of prostate cancer. Am J Pathol (2008) 1.85
Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res (2003) 1.83
Influence of slide aging on results of translational research studies using immunohistochemistry. Mod Pathol (2004) 1.75
FOXL2 and BPES: mutational hotspots, phenotypic variability, and revision of the genotype-phenotype correlation. Am J Hum Genet (2003) 1.70
Arterial neovascularization and inflammation in vulnerable patients: early and late signs of symptomatic atherosclerosis. Circulation (2004) 1.68
The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer (2011) 1.62
AMACR expression in colorectal cancer is associated with left-sided tumor localization. Virchows Arch (2008) 1.61
C3 deposition glomerulopathy due to a functional factor H defect. Kidney Int (2008) 1.61
A fluorescence in situ hybridization-based assay for improved detection of lung cancer cells in bronchial washing specimens. Cancer (2002) 1.60
Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. Cancer Res (2002) 1.58
Estrogen receptor β expression and androgen receptor phosphorylation correlate with a poor clinical outcome in hormone-naive prostate cancer and are elevated in castration-resistant disease. Endocr Relat Cancer (2013) 1.57
Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. Lancet Oncol (2012) 1.54
Intermediate-term results of retroperitoneoscopy-assisted cryotherapy for small renal tumours using multiple ultrathin cryoprobes. Eur Urol (2006) 1.53
GJA1 mutations, variants, and connexin 43 dysfunction as it relates to the oculodentodigital dysplasia phenotype. Hum Mutat (2009) 1.52
Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol (2008) 1.51
Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma. Am J Pathol (2003) 1.51
Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation. Eur Urol (2006) 1.50
Deletion, mutation, and loss of expression of KLF6 in human prostate cancer. Am J Pathol (2003) 1.50
VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol (2002) 1.48
Advancing a clinically relevant perspective of the clonal nature of cancer. Proc Natl Acad Sci U S A (2011) 1.47
HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res (2007) 1.45
Comparison of a multi-layer structural model for arterial walls with a fung-type model, and issues of material stability. J Biomech Eng (2004) 1.45
Seven hours to adequate antimicrobial therapy in urosepsis using isothermal microcalorimetry. J Clin Microbiol (2013) 1.45
The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod Pathol (2004) 1.44
Virtual slides: high-quality demand, physical limitations, and affordability. Hum Pathol (2003) 1.42
C4d staining of renal allograft biopsies: a comparative analysis of different staining techniques. Nephrol Dial Transplant (2006) 1.40
E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene (2004) 1.40
Retroperitoneoscopic living donor nephrectomy: a retrospective comparison to the open approach. Transplantation (2004) 1.39
Potential consequences of low biopsy core number in selection of patients with prostate cancer for current active surveillance protocols. Urology (2013) 1.39
Comparison of potassium-titanyl-phosphate laser vaporization of the prostate and transurethral resection of the prostate: update of a prospective non-randomized two-centre study. BJU Int (2008) 1.37
Lack of the transcriptional coactivator OBF-1 prevents the development of systemic lupus erythematosus-like phenotypes in Aiolos mutant mice. J Immunol (2003) 1.36
[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Clin Cancer Res (2007) 1.35
Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype. Breast Cancer Res (2008) 1.35
EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch (2012) 1.34
Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease. Hum Mutat (2008) 1.34
ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol (2010) 1.33
Different types of microsatellite instability in ovarian carcinoma. Int J Cancer (2004) 1.30
Predominance of high-grade pathway in breast cancer development of Middle East women. Mod Pathol (2005) 1.30
Calretinin expression in human normal and neoplastic tissues: a tissue microarray analysis on 5233 tissue samples. Hum Pathol (2003) 1.29
KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations. Clin Cancer Res (2004) 1.28
Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin Cancer Res (2010) 1.28
Cyclin E overexpression and amplification in human tumours. J Pathol (2003) 1.27
Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate (2003) 1.26
Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence. Clin Cancer Res (2005) 1.26
Enhanced expression of ANO1 in head and neck squamous cell carcinoma causes cell migration and correlates with poor prognosis. PLoS One (2012) 1.26
HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J Clin Pathol (2006) 1.24
Riluzole in the treatment of mood and anxiety disorders. CNS Drugs (2008) 1.24
Factors to keep in mind when introducing virtual microscopy. Virchows Arch (2005) 1.24
Polyomavirus nephropathy in native kidneys and renal allografts: an update on an escalating threat. Transpl Int (2006) 1.24
Hepatocyte paraffin 1 expression in human normal and neoplastic tissues: tissue microarray analysis on 3,940 tissue samples. Am J Clin Pathol (2004) 1.23
Basal activation of transcription factor signal transducer and activator of transcription (Stat5) in nonpregnant mouse and human breast epithelium. Mol Endocrinol (2002) 1.22
EphB2 expression across 138 human tumor types in a tissue microarray: high levels of expression in gastrointestinal cancers. Clin Cancer Res (2005) 1.21
ROS signaling by NOX4 drives fibroblast-to-myofibroblast differentiation in the diseased prostatic stroma. Mol Endocrinol (2011) 1.21
Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells. Cancer Res (2008) 1.21
Polyomavirus nephropathy: morphology, pathophysiology, and clinical management. Curr Opin Nephrol Hypertens (2003) 1.20
Tissue microarrays. Biotechniques (2004) 1.20
Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway. Endocrinology (2007) 1.19
Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo. Endocr Relat Cancer (2010) 1.16
Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer. Int J Cancer (2006) 1.15
Expression of voltage-gated potassium channels in human and mouse colonic carcinoma. Clin Cancer Res (2007) 1.15
HER2 analysis in breast cancer: reduced immunoreactivity in FISH non-informative cancer biopsies. Int J Oncol (2004) 1.15
Epstein syndrome: another renal disorder with mutations in the nonmuscle myosin heavy chain 9 gene. Hum Genet (2001) 1.15
Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. Hum Pathol (2010) 1.14
Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. Oncogene (2002) 1.14
Kidney transplants, antibodies and rejection: is C4d a magic marker? Nephrol Dial Transplant (2003) 1.13
Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5b has a preferential role in the promotion of prostate cancer cell viability and tumor growth. Am J Pathol (2010) 1.11
ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP, and TIMP action and affect cell migration: a comparison between mesothelioma and mesothelial cells. J Cell Physiol (2006) 1.11
Detection of ALK-positive non-small-cell lung cancers on cytological specimens: high accuracy of immunocytochemistry with the 5A4 clone. J Thorac Oncol (2013) 1.09
Epithelial growth factor receptor status in primary and recurrent ovarian cancer. Mod Pathol (2006) 1.09